supernus.com (SUPN) - Long-Term Liabilities to Capital

The share price of Supernus Pharmaceuticals (SUPN) visualized below helps assess the resilience of a business that relies on long-term demand for ADHD and epilepsy treatments, ensuring stable revenue streams. The current figure is 0.03. Jack Hatigian's team effectively implements new developments and protects patents. Simultaneously, Supernus Pharmaceuticals (SUPN) is capturing new markets, increasing its consumer base by expanding the therapeutic capabilities of its drugs.

Integrating ESG standards into the development of CNS drugs requires stable funding, a trend reflected in the long-term debt-to-equity ratio. This indicator correlates liabilities with a maturity of over one year to total equity, allowing analysts to separate speculative volatility from the fundamental debt load during M&A transactions. A low value confirms the financial stability of Supernus Pharmaceuticals (SUPN), ensuring security during a crisis.